VOYAGER THERAPEUTICS, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.57 USD | +1.06% |
|
-0.18% | +1.36% |
| May. 14 | Wedbush Adjusts Voyager Therapeutics' PT to $8 From $10, Keeps Neutral Rating | MT |
| May. 13 | Transcript : Voyager Therapeutics, Inc., Q1 2024 Earnings Call, May 13, 2024 |
Presenter SpeechTiago Fauth (Analysts)I'm Tiago Fauth from Credit Suisse, one of the analysts ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Voyager Therapeutics, Inc. is a biotechnology company focused on advancing neurogenetic medicines. The Companyâs pipeline includes programs for Alzheimerâs disease, amyotrophic lateral sclerosis (ALS), Parkinsonâs disease, and multiple other diseases of the central nervous system. Many of its programs are derived from its TRACER AAV capsid discovery platform, which is used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Its pipeline of programs, all of which are in preclinical development, include Anti-Tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy Program, Tau Silencing Gene Therapy Program, Vectorized Anti-Amyloid Antibody Early Research Program, Friedreichâs Ataxia Program: VY-FXN01, GBA1 Gene Replacement Program, HD Program, and others. VY-TAU01 is for the treatment of Alzheimerâs disease. SOD1 Silencing Gene Therapy Program is for the treatment of ALS.
Calendar
2024-06-05
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
8.48
USD
Average target price
17.56
USD
Spread / Average Target
+107.02%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +1.36% | 461M | |
| +29.41% | 49.18B | |
| +0.67% | 42.11B | |
| +50.47% | 40.37B | |
| -5.26% | 28.85B | |
| +13.68% | 26.09B | |
| -22.74% | 18.71B | |
| +8.22% | 13.26B | |
| +32.78% | 12.32B | |
| -1.37% | 11.99B |
- Stock Market
- Equities
- VYGR Stock
- News Voyager Therapeutics, Inc.
- Transcript : Voyager Therapeutics, Inc. Presents at Credit Suisse 28th Annual Healthcare Conference, Nov-13-2019 10
